CA-XRAN-FOUNDATION
27.2.2017 08:03:01 CET | Business Wire | Press release
The xRAN Foundation, a consortium dedicated to promoting a software-based, extensible Radio Access Network (xRAN) and to standardizing critical elements of the xRAN architecture, today announced that Verizon, a global leader of innovative mobile communications, technology and infrastructure and Ranzure, a provider of flexible, virtualized, cloud-based 4G/5G RAN solutions, have joined the xRAN Foundation. In addition to these key new members, the xRAN Foundation has announced a collaboration with M-CORD , the open source project reinventing network access to bring datacenter economics and cloud agility to service providers’ central offices.
“A network architecture that provides a robust, interactive abstraction layer between applications and RAN infrastructure fits very well with our vision and goals. We believe this approach creates opportunities to increase the efficiency of our network and improve the quality of experience for our subscribers,” said Adam Koeppe, Vice President, Network Technology Planning at Verizon. “The xRAN Foundation has demonstrated the feasibility of a decoupled approach. The combination of standardized north-bound and south-bound interfaces allows the development of applications that can intelligently interact with the RAN infrastructure in a way that has never been possible before. We are excited to join the xRAN Foundation and plan to actively evaluate solutions that support xRAN interfaces and architecture.”
“For an efficient delivery of next generation mobile services, such as AR, IoT and industrial robotics, a new more flexible software-based and hardware independent RAN architecture is required. The xRAN approach will offer us real time programmability and control of our RAN infrastructure to dynamically adapt to our customers' needs,” said Bruno Jacobfeuerborn, CTO, Deutsche Telekom. “We are excited to see xRAN and CORD Project join forces to drive the development of this approach.”
Formally formed in October of 2016 by AT&T, Deutsche Telekom, SK Telecom, Intel Corporation, Texas Instruments, Radisys, Aricent and Stanford University, the xRAN Foundation is a consortium dedicated to promoting a software-based, extensible Radio Access Network (xRAN) and to standardizing critical elements of the xRAN architecture. The xRAN architecture transforms today’s static, highly-proprietary RAN infrastructure into an extensible, software-based service delivery platform capable of rapidly responding to changing user, application and business needs.
The xRAN Foundation is holding a panel discussion event at Mobile World Congress 2017 in Barcelona on Tuesday February 28th at noon on the Deutsche Telekom main presentation stage in Hall 3. The event will include an introduction presentation by Deutche Telekom CTO, Bruno Jacobfeuerborn, followed by a panel discussion moderated by Petr Ledl, Head of Deutsche Telekom 5G:haus. The panel includes Dr. Sachi Katti, Stanford University, Dr. Kim Larsen, Technology Economics & Transformation (TET) & AI Technology Architecture & Innovation (TAI) Group Technology at Deutsche Telekom, Gordon Mansfield, Vice President RAN & Device Design at AT&T, and Caroline Chan, VP and GM, 5G Infrastructure Division, Network Platform Group, at Intel.
A multi-vendor demonstration of the xRAN controller, featuring the Intel + Radisys and the Texas Instruments + Aricent reference platforms, will be hosted during Mobile World Congress. Register for a demo here: http://xran.org/mwc
About xRAN Foundation
The xRAN Foundation was formed to develop, standardize and promote an open alternative to the traditionally closed, hardware-based RAN architecture. xRAN fundamentally advances RAN architecture in three areas – decouples the RAN control plane from the user plane, builds a modular eNB software stack that operates on common-off-the-shelf (COTS) hardware and publishes open north- and south-bound interfaces to the industry. For more information about xRAN Foundation membership go to xran.org/membership or email info@xran.org . For more information on xRAN architecture, download the xRAN Architecture white paper . To schedule a briefing with xRAN member representatives at Mobile World Congress in Barcelona, please contact pr@xran.org .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170226005155/en/
Contact:
xRAN Foundation
Rod Stuhlmuller
rod@xran.org
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom